Trial Profile
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 032
- Sponsors Bristol-Myers Squibb
- 19 Jan 2024 This trial has been completed in Denmark.
- 20 Dec 2023 Results assessing unanchored population-adjusted indirect comparisons methods through a case study in third-line small-cell lung cancer comparing nivolumab to standard of care based on a single-arm phase II trial (CheckMate 032) and real-world study (Flatiron) for time-to-event outcomes using regression adjustment, inverse odds weighting, and doubly robust methods with either individual patient or aggregate data, published in the Value in Health.
- 13 Dec 2023 Planned End Date changed from 31 Dec 2023 to 30 May 2024.